Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.
Identifieur interne : 002752 ( Main/Exploration ); précédent : 002751; suivant : 002753Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.
Auteurs : Eric J. Sigler [États-Unis] ; John C. Randolph ; Jorge I. Calzada ; Steve CharlesSource :
- Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [ 1435-702X ] ; 2013.
Descripteurs français
- KwdFr :
- Acuité visuelle (physiologie), Angiographie fluorescéinique (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Bévacizumab (MeSH), Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Femelle (MeSH), Humains (MeSH), Inhibiteurs de l'angiogenèse (usage thérapeutique), Injections intravitréennes (MeSH), Membrane basale (chirurgie), Mâle (MeSH), Observation (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Tomographie par cohérence optique (MeSH), Télangiectasie rétinienne (chirurgie), Télangiectasie rétinienne (physiopathologie), Télangiectasie rétinienne (thérapie), Télangiectasie rétinienne (traitement médicamenteux), Vitrectomie (MeSH), Études de suivi (MeSH), Études rétrospectives (MeSH).
- MESH :
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- chirurgie : Membrane basale, Télangiectasie rétinienne.
- physiologie : Acuité visuelle.
- physiopathologie : Télangiectasie rétinienne.
- thérapie : Télangiectasie rétinienne.
- traitement médicamenteux : Télangiectasie rétinienne.
- usage thérapeutique : Anticorps monoclonaux humanisés, Inhibiteurs de l'angiogenèse.
- Angiographie fluorescéinique, Bévacizumab, Femelle, Humains, Injections intravitréennes, Mâle, Observation, Résultat thérapeutique, Sujet âgé, Tomographie par cohérence optique, Vitrectomie, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Aged (MeSH), Angiogenesis Inhibitors (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Basement Membrane (surgery), Bevacizumab (MeSH), Female (MeSH), Fluorescein Angiography (MeSH), Follow-Up Studies (MeSH), Humans (MeSH), Intravitreal Injections (MeSH), Male (MeSH), Observation (MeSH), Retinal Telangiectasis (drug therapy), Retinal Telangiectasis (physiopathology), Retinal Telangiectasis (surgery), Retinal Telangiectasis (therapy), Retrospective Studies (MeSH), Tomography, Optical Coherence (MeSH), Treatment Outcome (MeSH), Vascular Endothelial Growth Factor A (antagonists & inhibitors), Visual Acuity (physiology), Vitrectomy (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized.
- drug therapy : Retinal Telangiectasis.
- physiology : Visual Acuity.
- physiopathology : Retinal Telangiectasis.
- surgery : Basement Membrane, Retinal Telangiectasis.
- therapy : Retinal Telangiectasis.
- Aged, Bevacizumab, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Intravitreal Injections, Male, Observation, Retrospective Studies, Tomography, Optical Coherence, Treatment Outcome, Vitrectomy.
Abstract
PURPOSE
To compare visual and anatomic outcomes in eyes with type 2 idiopathic macular telangiectasia (Mactel) treated with either intravitreal bevacizumab (IVB), observation, or pars plana vitrectomy (PPV) with internal limiting membrane removal.
METHODS
Retrospective, consecutive, interventional case series of phakic patients with Mactel. Best-corrected Snellen visual acuity (BCVA) and complete ophthalmic exam was obtained prior to treatment and at subsequent 3-month intervals for a minimum of 6 months. Fluorescein angiographic and spectral-domain optical coherence tomography features were examined, and compared to BCVA at treatment initiation and follow-up.
RESULTS
Fifty-six eyes of 28 patients were evaluated. Mean age was 65 ± 12 years, and mean follow-up was 24 ± 13 months. Patients were treated with either observation (n = 33), IVB (n = 15), or PPV (n = 8). Mean number of treatments for the IVB group was 2.5 ± 3.5 intravitreal injections. No significant differences in BCVA change were observed between treatment groups via one-way ANOVA (p = 0.49). Presence of inner retinal cysts was not correlated to BCVA (p > 0.05). Discontinuous outer nuclear layer was significantly related to worse initial and final vision, but not to BCVA change.
CONCLUSION
IVB and PPV with ILM removal appear ineffective in improving visual outcome in eyes with non-proliferative Mactel. SD-OCT evidence of disrupted foveal outer nuclear layer is related to decreased BCVA, but not related to BCVA change following treatment.
DOI: 10.1007/s00417-012-2150-1
PubMed: 22948950
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.</title><author><name sortKey="Sigler, Eric J" sort="Sigler, Eric J" uniqKey="Sigler E" first="Eric J" last="Sigler">Eric J. Sigler</name><affiliation wicri:level="2"><nlm:affiliation>Charles Retina Institute, 6401 Poplar Ave. Suite 190, Memphis, TN 38119, USA. ejsigler@gmail.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Charles Retina Institute, 6401 Poplar Ave. Suite 190, Memphis, TN 38119</wicri:regionArea><placeName><region type="state">Tennessee</region></placeName></affiliation></author><author><name sortKey="Randolph, John C" sort="Randolph, John C" uniqKey="Randolph J" first="John C" last="Randolph">John C. Randolph</name></author><author><name sortKey="Calzada, Jorge I" sort="Calzada, Jorge I" uniqKey="Calzada J" first="Jorge I" last="Calzada">Jorge I. Calzada</name></author><author><name sortKey="Charles, Steve" sort="Charles, Steve" uniqKey="Charles S" first="Steve" last="Charles">Steve Charles</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22948950</idno><idno type="pmid">22948950</idno><idno type="doi">10.1007/s00417-012-2150-1</idno><idno type="wicri:Area/Main/Corpus">002900</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">002900</idno><idno type="wicri:Area/Main/Curation">002900</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">002900</idno><idno type="wicri:Area/Main/Exploration">002900</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.</title><author><name sortKey="Sigler, Eric J" sort="Sigler, Eric J" uniqKey="Sigler E" first="Eric J" last="Sigler">Eric J. Sigler</name><affiliation wicri:level="2"><nlm:affiliation>Charles Retina Institute, 6401 Poplar Ave. Suite 190, Memphis, TN 38119, USA. ejsigler@gmail.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Charles Retina Institute, 6401 Poplar Ave. Suite 190, Memphis, TN 38119</wicri:regionArea><placeName><region type="state">Tennessee</region></placeName></affiliation></author><author><name sortKey="Randolph, John C" sort="Randolph, John C" uniqKey="Randolph J" first="John C" last="Randolph">John C. Randolph</name></author><author><name sortKey="Calzada, Jorge I" sort="Calzada, Jorge I" uniqKey="Calzada J" first="Jorge I" last="Calzada">Jorge I. Calzada</name></author><author><name sortKey="Charles, Steve" sort="Charles, Steve" uniqKey="Charles S" first="Steve" last="Charles">Steve Charles</name></author></analytic><series><title level="j">Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</title><idno type="eISSN">1435-702X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Basement Membrane (surgery)</term><term>Bevacizumab (MeSH)</term><term>Female (MeSH)</term><term>Fluorescein Angiography (MeSH)</term><term>Follow-Up Studies (MeSH)</term><term>Humans (MeSH)</term><term>Intravitreal Injections (MeSH)</term><term>Male (MeSH)</term><term>Observation (MeSH)</term><term>Retinal Telangiectasis (drug therapy)</term><term>Retinal Telangiectasis (physiopathology)</term><term>Retinal Telangiectasis (surgery)</term><term>Retinal Telangiectasis (therapy)</term><term>Retrospective Studies (MeSH)</term><term>Tomography, Optical Coherence (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term><term>Visual Acuity (physiology)</term><term>Vitrectomy (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acuité visuelle (physiologie)</term><term>Angiographie fluorescéinique (MeSH)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Bévacizumab (MeSH)</term><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Injections intravitréennes (MeSH)</term><term>Membrane basale (chirurgie)</term><term>Mâle (MeSH)</term><term>Observation (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Tomographie par cohérence optique (MeSH)</term><term>Télangiectasie rétinienne (chirurgie)</term><term>Télangiectasie rétinienne (physiopathologie)</term><term>Télangiectasie rétinienne (thérapie)</term><term>Télangiectasie rétinienne (traitement médicamenteux)</term><term>Vitrectomie (MeSH)</term><term>Études de suivi (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Membrane basale</term><term>Télangiectasie rétinienne</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Retinal Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Acuité visuelle</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Visual Acuity</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Télangiectasie rétinienne</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Retinal Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Basement Membrane</term><term>Retinal Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Retinal Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Télangiectasie rétinienne</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Télangiectasie rétinienne</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Bevacizumab</term><term>Female</term><term>Fluorescein Angiography</term><term>Follow-Up Studies</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Observation</term><term>Retrospective Studies</term><term>Tomography, Optical Coherence</term><term>Treatment Outcome</term><term>Vitrectomy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Angiographie fluorescéinique</term><term>Bévacizumab</term><term>Femelle</term><term>Humains</term><term>Injections intravitréennes</term><term>Mâle</term><term>Observation</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tomographie par cohérence optique</term><term>Vitrectomie</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>To compare visual and anatomic outcomes in eyes with type 2 idiopathic macular telangiectasia (Mactel) treated with either intravitreal bevacizumab (IVB), observation, or pars plana vitrectomy (PPV) with internal limiting membrane removal.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Retrospective, consecutive, interventional case series of phakic patients with Mactel. Best-corrected Snellen visual acuity (BCVA) and complete ophthalmic exam was obtained prior to treatment and at subsequent 3-month intervals for a minimum of 6 months. Fluorescein angiographic and spectral-domain optical coherence tomography features were examined, and compared to BCVA at treatment initiation and follow-up.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Fifty-six eyes of 28 patients were evaluated. Mean age was 65 ± 12 years, and mean follow-up was 24 ± 13 months. Patients were treated with either observation (n = 33), IVB (n = 15), or PPV (n = 8). Mean number of treatments for the IVB group was 2.5 ± 3.5 intravitreal injections. No significant differences in BCVA change were observed between treatment groups via one-way ANOVA (p = 0.49). Presence of inner retinal cysts was not correlated to BCVA (p > 0.05). Discontinuous outer nuclear layer was significantly related to worse initial and final vision, but not to BCVA change.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>IVB and PPV with ILM removal appear ineffective in improving visual outcome in eyes with non-proliferative Mactel. SD-OCT evidence of disrupted foveal outer nuclear layer is related to decreased BCVA, but not related to BCVA change following treatment.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22948950</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-702X</ISSN><JournalIssue CitedMedium="Internet"><Volume>251</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</Title><ISOAbbreviation>Graefes Arch Clin Exp Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.</ArticleTitle><Pagination><MedlinePgn>1097-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00417-012-2150-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare visual and anatomic outcomes in eyes with type 2 idiopathic macular telangiectasia (Mactel) treated with either intravitreal bevacizumab (IVB), observation, or pars plana vitrectomy (PPV) with internal limiting membrane removal.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective, consecutive, interventional case series of phakic patients with Mactel. Best-corrected Snellen visual acuity (BCVA) and complete ophthalmic exam was obtained prior to treatment and at subsequent 3-month intervals for a minimum of 6 months. Fluorescein angiographic and spectral-domain optical coherence tomography features were examined, and compared to BCVA at treatment initiation and follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-six eyes of 28 patients were evaluated. Mean age was 65 ± 12 years, and mean follow-up was 24 ± 13 months. Patients were treated with either observation (n = 33), IVB (n = 15), or PPV (n = 8). Mean number of treatments for the IVB group was 2.5 ± 3.5 intravitreal injections. No significant differences in BCVA change were observed between treatment groups via one-way ANOVA (p = 0.49). Presence of inner retinal cysts was not correlated to BCVA (p > 0.05). Discontinuous outer nuclear layer was significantly related to worse initial and final vision, but not to BCVA change.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IVB and PPV with ILM removal appear ineffective in improving visual outcome in eyes with non-proliferative Mactel. SD-OCT evidence of disrupted foveal outer nuclear layer is related to decreased BCVA, but not related to BCVA change following treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sigler</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Charles Retina Institute, 6401 Poplar Ave. Suite 190, Memphis, TN 38119, USA. ejsigler@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Calzada</LastName><ForeName>Jorge I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Charles</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Graefes Arch Clin Exp Ophthalmol</MedlineTA><NlmUniqueID>8205248</NlmUniqueID><ISSNLinking>0721-832X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001485" MajorTopicYN="N">Basement Membrane</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="N">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058456" MajorTopicYN="N">Retinal Telangiectasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014821" MajorTopicYN="Y">Vitrectomy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22948950</ArticleId><ArticleId IdType="doi">10.1007/s00417-012-2150-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1711-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21938453</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Ophthalmol. 2010 Jul;54(4):320-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20700800</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye (Lond). 2010 Oct;24(10):1535-41; quiz 1542</Citation><ArticleIdList><ArticleId IdType="pubmed">20865030</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 2009 Jan;29(1):27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18936721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmic Surg Lasers Imaging. 2010 Jul 29;41 Online:1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21158375</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 2008 Feb;28(2):314-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18301037</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 1999;19(4):332-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10458300</ArticleId></ArticleIdList></Reference><Reference><Citation>Trans Ophthalmol Soc U K. 1980 Apr;100(Pt 1):162-70</Citation><ArticleIdList><ArticleId IdType="pubmed">6943823</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ophthalmol. 1982 May;100(5):769-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7082207</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye (Lond). 2010 Jun;24(6):1119</Citation><ArticleIdList><ArticleId IdType="pubmed">19798109</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ophthalmol. 2006 Apr;124(4):450-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16606869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 1997 Nov;104(11):1838-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9373114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2007 Sep;114(9):1736-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17822979</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2011 May;151(5):876-886.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">21334595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmologica. 1993;207(1):9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8278175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmic Surg Lasers Imaging. 2007 Mar-Apr;38(2):164-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17396701</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Ophthalmol. 2008 Jul;92(7):941-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18577646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 1993 Oct;100(10):1536-46</Citation><ArticleIdList><ArticleId IdType="pubmed">8414413</ArticleId></ArticleIdList></Reference><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2007 Jun;245(6):783-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17120013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2010 Dec;117(12):2407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20678804</ArticleId></ArticleIdList></Reference><Reference><Citation>Arq Bras Oftalmol. 2006 Nov-Dec;69(6):941-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17273694</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 2012 May;32(5):996-1006</Citation><ArticleIdList><ArticleId IdType="pubmed">22266930</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ophthalmol. 1999 Jun;117(6):821-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10369597</ArticleId></ArticleIdList></Reference><Reference><Citation>Klin Monbl Augenheilkd. 2007 Oct;224(10):787-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17952823</ArticleId></ArticleIdList></Reference><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18386039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):120-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16583633</ArticleId></ArticleIdList></Reference><Reference><Citation>Retina. 2011 Oct;31(9):1848-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21610563</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ophthalmol. 1968 Nov;80(5):592-605</Citation><ArticleIdList><ArticleId IdType="pubmed">5684308</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2010 Jul;150(1):55-62.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">20609708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Tennessee</li></region></list><tree><noCountry><name sortKey="Calzada, Jorge I" sort="Calzada, Jorge I" uniqKey="Calzada J" first="Jorge I" last="Calzada">Jorge I. Calzada</name><name sortKey="Charles, Steve" sort="Charles, Steve" uniqKey="Charles S" first="Steve" last="Charles">Steve Charles</name><name sortKey="Randolph, John C" sort="Randolph, John C" uniqKey="Randolph J" first="John C" last="Randolph">John C. Randolph</name></noCountry><country name="États-Unis"><region name="Tennessee"><name sortKey="Sigler, Eric J" sort="Sigler, Eric J" uniqKey="Sigler E" first="Eric J" last="Sigler">Eric J. Sigler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002752 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002752 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22948950
|texte= Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22948950" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |